Topic

Articles

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

CytoReason Announces Expanded Collaboration Deal with Pfizer

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence. 

Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Ensysce Biosciences and Quotient Sciences Announce Partnership 

Feliza Mirasol is the science editor for 

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

Biotech Incubators Cultivate a Global Scene

Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.

Emergence Therapeutics to License Synaffix ADC Technology Platform in Deal Worth Up to $360 Million

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

A thorough understanding of both regulatory requirements and study challenges can help develop and validate the appropriate methods for a bioanalytical study program.

Aiding Regulatory Submissions Through Robust Bioanalytical Studies

Salipro has been granted patents in the United States and China for its proprietary technology to enable the development of therapeutics against challenging drug targets.

Salipro Biotech Obtains Patents in US and China for Direct Extraction of Membrane Proteins and Library Generation

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.


Avance Clinical Acquires C3 Research Associates

Roche’s acquisition of Good Therapeutics grants them rights to the company's conditionally activated PD-1-regulated IL-2 program.

Roche to Acquire Good Therapeutics for $250 Million

SIRIO is enhancing its strategy for small and medium nutrition brands as Lonza’s Sara Lesina joins as GM in Europe.

BioBusiness